Invocare

InvoCare is under Algo Engine buy conditions.

In mid-April IVC announced up to $250m equity raising
at $10.40/share.

April revenue was down 13% and we’re seeing costs higher than
anticipated. Improvement in trading conditions should occur as the partial easing of restrictions take place.

We assume 2020 earnings will be down 10% and see a recovery into 2021 & 2022.

We’ll revisit IVC if it trades back below $10.00

Invocare – Offers Long-Term Value

InvoCare is under current Algo Engine sell conditions, following a recent lower high formation at $15.00.

Invocare’s balance sheet will be strengthened following the announced raising of up to A$85m, via institutional placement which will include $20m via a share purchase plan. We expect this to be done at around $13.30.

We anticipate the next signal to be a Algo Engine “buy” and we’re likely to see this before the end of April.

We see long-term value in IVC and suggest investors watch for an entry signal between $13.30 & $13.80

 

 

 

Invocare – Renewed Buying Interest

Invocare has under performed following their recent earnings report, in which the company indicated flat forward earnings and an increase in capital expenditure.

Technically, a “higher low” formation remains in place and we flag to our readers the strength in today’s price action.

IVC

Invocare – FY17 Earnings

IVC’s FY17 result overall was slightly above our market expectations, although FY18 outlook guidance was disappointing.

FY17 underlying EBITDA increased 8% to $124 million, the result was driven by 2% revenue growth.

Based on FY19 EPS of $0.68 and DPS $0.48, IVC now trades on a forward yield of 3.4%.

IVC

Algo Update – Invocare

Our Algo Engine triggered a recent buy signal in IVC and the stock has continued to drift lower.

The next range of support is $14.30 , followed by the up trending support line marked as “support 2” in the graph below.

The negative price action over recent days is being driven by the market’s reaction to a change in industry competition in the UK and concerns that similar challenges may emerge in Australia.

IVC reports full year earnings result on 19th February.

InvoCare

Invocare – Approaching Buy Support

Our Algo Engine recently triggered a buy signal in IVC  at $15.71.

With the stock trading on a forward yield of 3% and underlying earnings growth of 8%, we feel investors should be watching for a near-term entry point.

FY18 NPAT is forecast to be $67m, EPS $0.61 and DPS $0.47 fully franked.

Invocare